24722284 |
Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression
Lee, BS,
Kang, S,
Song, YJ,
Cha, HY,
Kim, CH,
Kim, KA,
Cheong, KH
|
Cell Death Dis |
2014 |
23882082 |
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
Greve, J,
Phillips, HS,
Romero, M,
Peng, J,
Lim, A,
Yansura, DG,
Kaufman, DW,
Santell, L,
Lazarus, RA,
Nishimura, M,
Young, JC,
Ma, X,
Zheng, Z,
Su, Y,
Yang, NY,
Maun, HR,
Starovasnik, MA,
Merchant, M,
Mai, E,
Reilly, DE,
Zhang, YW,
Moffat, B,
Vande Woude, GF,
Huang, A,
Duenas, ET,
Xiang, H,
Billeci, KL,
Schwall, RH,
Dennis, MS
|
Proc Natl Acad Sci U S A |
2013 |
23208509 |
Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody
Lee, JM,
Kim, KA,
Song, YJ,
Han, YK,
Jeong, Y,
Choi, J,
Lee, S,
Choi, H,
Cheong, KH,
Kim, B,
Oh, YM,
Lee, SB,
Song, PH,
Jung, S,
Kim, DU,
Kim, GW,
Park, HW
|
Oncogene |
2014 |
26141862 |
Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling
Ginestier, C,
Roux, B,
Heukers, R,
Hanssens, V,
De Jonge, N,
Hultberg, A,
Silence, K,
Saunders, M,
Festjens, E,
De Boeck, G,
Huyghe, L,
Thibault, A,
Charafe-Jauffret, E,
de Haard, H,
Lamballe, F,
Michieli, P,
Dreier, T,
Blanchetot, C,
Morello, V,
Maina, F,
Brouckaert, P
|
Cancer Res |
2015 |
25231402 |
LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth
Wortinger, MA,
Chow, CK,
Wacheck, V,
Manro, JR,
Xia, J,
Tang, Y,
Lu, J,
Cornwell, P,
Wang, Y,
Huang, L,
Yan, SB,
Zeng, W,
Vaillancourt, P,
Denning, I,
Stephens, JR,
Credille, KM,
Tetreault, JW,
Ballard, DW,
Liu, L,
Peek, VL,
Davies, J,
Brown-Augsburger, P
|
Clin Cancer Res |
2014 |